Anti-Hypertensive Drugs - Belarus

Belarus

In Belarus, the revenue in the Anti-Hypertensive Drugs market is forecasted to reach US$5.25m by 2024.
It is anticipated that there will be an annual growth rate of -0.42% (CAGR 2024-2029), leading to a market volume of US$5.14m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$12,290.00m in 2024.
The demand for anti-hypertensive drugs in Belarus has surged due to the rising prevalence of hypertension among the elderly population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

Belarus, a country located in Eastern Europe, has been experiencing a steady growth in the Anti-Hypertensive Drugs market.

Customer preferences: The Belarusian population has been showing an increased awareness of the importance of maintaining a healthy lifestyle, which includes regular check-ups and medication intake for chronic diseases such as hypertension. Additionally, the aging population in Belarus has been contributing to the growth of the Anti-Hypertensive Drugs market, as hypertension is more prevalent among older adults.

Trends in the market: The Anti-Hypertensive Drugs market in Belarus has been witnessing a shift towards generic drugs, which are more affordable than their brand-name counterparts. This trend is in line with the global trend of increasing demand for generic drugs due to rising healthcare costs. However, the market for branded drugs is still significant, as some consumers prefer to pay more for drugs that they perceive to be of higher quality.

Local special circumstances: Belarus has a state-controlled healthcare system, which means that the government plays a significant role in regulating drug prices and determining which drugs are available for consumers. This has led to a situation where certain drugs may be more difficult to obtain than others, depending on the government's policies.

Underlying macroeconomic factors: Belarus has been experiencing a period of economic instability, which has led to a decline in disposable income for many consumers. However, the government's efforts to control drug prices have helped to make Anti-Hypertensive Drugs more affordable for the population. Additionally, the country's relatively low labor costs have made it an attractive location for pharmaceutical companies to manufacture drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.